Effect of Interval Cancer and Screening Process on Survival and Disease-free Period in Breast Cancer
Palabras clave
Abstracto
Descripción
The general objective for this study is to evaluate the survival and disease-free period of women participating in screening programs for breast cancer with a cancer diagnosed during the screening or an interval cancer, specifically true interval cancers and false negatives.
The cohort has information of women participating in breast cancer screening programs in Spain between 2000 and 2009, with a breast cancer diagnosed during the screening or between the screening interval (interval cancer), specifically true interval cancers and false negatives. The investigators obtained woman-related information (including breast density), tumor-related information (including tumor phenotype), and follow-up information (including relapses, second neoplasms and vital status at the end of follow up (June 2014)).
Expected results: Nowadays there are no results of cohort analysis of the diagnostic process of care that integrates all those different aspects. This study will complement the evaluation of population screening, specifically the interval cancer and the impact on survival and disease-free period taking into account relevant variables like breast density, tumor phenotype, clinical complications, readmissions, and the surgical approach.
This study is part of a broader project (CAMISS study) coordinated by the Evaluation of Health Services of Epidemiology and Public Health Group, which consists of two cohorts of women diagnosed with breast cancer: a prospective cohort (n=2,040 incident cases of breast cancer diagnosed in 18 hospitals of 5 Spanish regions) (Identifier in ClinicalTrials.gov: NCT02439554) and a retrospective cohort of screened women diagnosed with breast cancer between 2000 and 2009 in two Spanish regions (n=1,086).
The general objective of the CAMISS study is to evaluate different aspects of health care received by patients with breast cancer like the diagnostic process, treatment, complications, survival, costs and quality of life to provide information to improve the effectiveness and cost-effectiveness of interventions, reduce variability, have better predictive rules and increase the quality of life.
fechas
| Verificado por última vez: | 04/30/2017 |
| Primero enviado: | 05/17/2017 |
| Inscripción estimada enviada: | 05/21/2017 |
| Publicado por primera vez: | 05/23/2017 |
| Última actualización enviada: | 05/21/2017 |
| Última actualización publicada: | 05/23/2017 |
| Fecha de inicio real del estudio: | 12/31/2012 |
| Fecha estimada de finalización primaria: | 06/29/2014 |
| Fecha estimada de finalización del estudio: | 12/30/2015 |
Condición o enfermedad
Intervención / tratamiento
Procedure: Screened women with breast cancer
Procedure: Screened women with breast cancer
Fase
Grupos de brazos
| Brazo | Intervención / tratamiento |
|---|---|
| Screened women with breast cancer | Procedure: Screened women with breast cancer Cancers detected as a result of screening mammograms. |
Criterio de elegibilidad
| Edades elegibles para estudiar | 50 Years A 50 Years |
| Sexos elegibles para estudiar | Female |
| Método de muestreo | Non-Probability Sample |
| Acepta voluntarios saludables | si |
| Criterios | Inclusion Criteria: - Women aged between 50 to 69 years with invasive or in situ breast cancer. Exclusion Criteria: - Women diagnosed with lobular carcinoma in situ. |
Salir
Medidas de resultado primarias
1. Mortality [From date of cancer diagnosis until the date of death from any cause, assessed up to 14 years]
Medidas de resultado secundarias
1. Recurrences and second breast neoplasms [From date of cancer diagnosis until the date of the first recurrence or second breast neoplasm, whichever came first, assessed up to 14 years]
2. Treatment-related complications [From the date of surgery until the end of follow-up, assessed up to 14 years.]
3. Readmissions to hospital for reasons related to breast cancer [From the date of surgery until the end of follow-up, assessed up to 14 years.]
